Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04537910 · ClinicalTrials.gov registry record · Phase 1

A Study of LY3819253 (LY-CoV555) in Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
1
Study location

NCT04537910: Completed Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

NCT04537910 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 25 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04537910, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last up to 16 weeks and may include up to six visits to the study center, with a one-week overnight stay.

Primary Outcome

PK: AUC\[0-∞\] of LY3819253

Conditions Studied

Healthy

Interventions

  • DRUG Placebo
  • DRUG LY3819253

Study Locations (1)

Florida

  • Covance Clinical Research Inc - Daytona Beach

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2020-09-02
Est. Completion 2020-12-28
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What the finished NCT04537910 record still lists

NCT04537910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04537910 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT04537910 about?

NCT04537910 is a clinical study titled "A Study of LY3819253 (LY-CoV555) in Healthy Participants". The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last up...

What is the current status of trial NCT04537910?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2020-09-02. Estimated completion is 2020-12-28.

What conditions does trial NCT04537910 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT04537910?

The interventions under investigation include: Placebo (DRUG), LY3819253 (DRUG).

Who is sponsoring clinical trial NCT04537910?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04537910 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04537910's enrollment target sits among peer trials

25 778th of 1090 higher than 301 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04537910, the US trial registry maintained by the National Library of Medicine. NCT04537910 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.